Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2001

View Archived Issues

GlaxoSmithKline updates R&D activities --merger makes way for robust pipeline

NIH licensing opportunity: simian-human HAV chimeras

NIH licensing opportunity: novel antimalarial naphthylisoquinoline alkaloid compounds

Method of producing water-soluble aminoflavone analogues available for licensing from NIH

St. Jude and GlaxoSmithKline awarded grant for multidrug-resistant tuberculosis research

Maxygen and IAVI to develop novel AIDS vaccines

Positive quality-of-life and survival results reported for Maxim's Ceplene

BioMarin reports product development update

2000 achievements at Corixa discussed

U.S. researchers design chaperone-binding antifibrillogenic peptide

Inhibition of caspase 2 or 3 may be beneficial in cerebral vasospasm following SAH

FDA Antiviral Drugs Advisory Committee recommends approval of Roche's valganciclovir

Interneuron's PRO-2000 to enter phase II/III NIH-supported HIV prevention trial

FDA grants approval for Reminyl as treatment of Alzheimer's disease

SeMet induces cell cycle alterations, growth inhibition and apoptosis in colon cancer cells

BACE1-deficient mice exhibit normal phenotype although beta-amyloid generation is abolished

InKine cleared to proceed with Colirest pivotal trial for treatment of Crohn's disease

Neurotrophic agents emerge en masse from Vertex pipeline

Kaneka isolates and synthesizes new steroid glycosides with antitumor activity

Selective Y5 receptor antagonists identified in Synaptic/Novartis collaboration

Japanese patent issued to Santen for new agents for glaucoma

Endothelial function improved by ETA antagonist in CHF patients

NeoPharm's CRADA agreement for IL-13 receptor research extended

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...